Korenberg Matthew E — SEC Form 4 filings
SEC reporting owner CIK 1649903. 15 Form 4 filings on record with FilingPulse; latest filed 2026-06-16.
Transaction summary — filings shown
Covers all 15 filings on record, filed 2024-02-16 to 2026-06-16. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 13 legs across 4 filings — 70,748 shares, $6,921,652 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 31.
- Largest priced transaction: sale of 18,245 shares @ $98.50 ($1,797,132) in LIGAND PHARMACEUTICALS INC, filed 2024-08-13.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| LIGAND PHARMACEUTICALS INC (LGND) | President & COO | 8 | — | 13 legs · 70,748 sh · $6,921,652 | 22 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | CFO, Treasurer | 4 | — | — | 6 |
| LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) | Director | 3 | — | — | 3 |
Form 4 filings — Korenberg Matthew E
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-16 | 4 | PALVELLA THERAPEUTICS, INC. (PVLA) | Option exercise (M): 1,000 @ $13.60 · Option exercise (M): 1,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) | Grant/award (A): 25,907 | EDGAR |
| 2026-02-09 | 4 | PALVELLA THERAPEUTICS, INC. (PVLA) | Grant/award (A): 44,123 (derivative) @ $0 | EDGAR |
| 2025-07-17 | 4 | LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) | Grant/award (A): 19,506 | EDGAR |
| 2025-02-10 | 4/A | PALVELLA THERAPEUTICS, INC. (PVLA) | Grant/award (A): 5,373 (derivative) @ $0 · Grant/award (A): 123,559 (derivative) @ $0 | EDGAR |
| 2024-12-17 | 4 | PALVELLA THERAPEUTICS, INC. (PVLA) | Grant/award (A): 167,100 (derivative) @ $0 | EDGAR |
| 2024-09-24 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Option exercise (M): 4,982 @ $49.99 · Sale (S): 6,275 @ $104.10 · Option exercise (M): 395 @ $49.99 · Option exercise (M): 9,377 @ $52.84 · Sale (S): 2,481 @ $100.05 · Sale (S): 7,090 @ $101.61 · +4 more | EDGAR |
| 2024-09-18 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Option exercise (M): 914 @ $55.75 · Tax withholding (F): 485 @ $105 · Option exercise (M): 849 @ $58.49 · Tax withholding (F): 472 @ $105 · Option exercise (M): 671 @ $49.99 · Tax withholding (F): 319 @ $105 · +6 more | EDGAR |
| 2024-08-26 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Sale (S): 1,157 @ $105.54 · Sale (S): 2,037 @ $104.09 · Sale (S): 4,275 @ $105.13 · Sale (S): 6,177 @ $105.02 · Sale (S): 5,212 @ $106.32 | EDGAR |
| 2024-08-21 | 4 | LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) | Grant/award (A): 24,554 | EDGAR |
| 2024-08-13 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Sale (S): 18,245 @ $98.50 | EDGAR |
| 2024-07-02 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Other (J): 350 @ $60.71 | EDGAR |
| 2024-05-15 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Sale (S): 3,440 @ $84.54 · Sale (S): 13,638 @ $85.08 · Sale (S): 520 @ $85.68 | EDGAR |
| 2024-02-29 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Grant/award (A): 14,416 @ $0 · Grant/award (A): 58,544 (derivative) @ $0 | EDGAR |
| 2024-02-16 | 4 | LIGAND PHARMACEUTICALS INC (LGND) | Tax withholding (F): 4,778 @ $74.65 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1649903 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →